InVivo Therapeutics has begun shipment of its degradable polymer Neuro-Spinal Scaffold for spinal cord injury (SCI) patients, for initiation of the company’s first clinical trial. In preclinical studies, the Neuro-Spinal Scaffold promoted cell adhesion, neurite sprouting, the growth of remodeled spinal cord tissue containing myelinated axons, and improved motor function.
They are currently recruiting in Arizona and North Carolina USA. Patients will be within 10 days of injury, non-penetrating ASIA-A injuries between T3 and T11.